SCHEDULE 13G/A: ARK Investment Management Discloses 8.47% Stake in Recursion Pharmaceuticals

ARK Investment Management LLC has filed an amended Schedule 13G, revealing a beneficial ownership of 8.47% of Recursion Pharmaceuticals, Inc.'s Class A Common Stock as of December 31, 2024.

Summary

• ARK Investment Management LLC reported beneficial ownership of 32,346,397 shares of Recursion Pharmaceuticals, Inc. Class A Common Stock.
• This represents 8.47% of the Class A Common Stock outstanding.
• As of December 31, 2024, ARK Investment Management LLC held sole voting power over 30,689,945 shares and shared voting power over 552,872 shares.
• The firm also held sole dispositive power over 32,346,397 shares and no shared dispositive power.
• The filing is an Amendment No. 2 to a previous Schedule 13G, indicating an update to their reported holdings.

Sentiment

Score: 6

Explanation: The disclosure of a significant stake by a prominent institutional investor like ARK Investment Management LLC is generally viewed as a positive signal, indicating confidence in the company. However, the filing itself does not provide operational or financial performance details, limiting the overall sentiment score.

Positives

• A significant stake (8.47%) held by a prominent investment management firm like ARK Investment Management LLC may signal confidence in Recursion Pharmaceuticals, Inc.'s long-term prospects.
• The holding is stated to be acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, suggesting a passive investment strategy.

Negatives

• The Schedule 13G filing itself does not contain information that would typically be categorized as negative regarding the issuer's operational performance or financial outlook.

Risks

• The document does not detail specific risks related to Recursion Pharmaceuticals, Inc.'s operations or financial health. The primary risk inherent in such a filing is the potential for large block sales by the reporting person, which could impact share price.

Future Outlook

NA

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by ARK Investment Management LLC in Recursion Pharmaceuticals, Inc. Such filings are standard disclosures required when an entity acquires more than 5% of a company's outstanding shares, providing transparency on large institutional holdings. For the biotechnology and pharmaceutical industry, a substantial investment from a well-known fund like ARK can sometimes be interpreted by the market as a vote of confidence in the company's innovative potential or strategic direction, especially given ARK's focus on disruptive technologies.

Stakeholder Impact

• Shareholders: Increased transparency regarding a major institutional holder. The presence of a large, well-known investor might positively influence market perception and potentially share price stability.
• Company Management: Awareness of a significant passive investor, though the filing states the holding is not for control purposes.

Key Dates

Keywords

Recursion Pharmaceuticals, ARK Investment Management, Schedule 13G, beneficial ownership, Class A Common Stock, institutional investor, SEC filing, equity stake, investment adviser